Black Diamond Therapeutics (BDTX) Short-term Investments (2020 - 2026)

Black Diamond Therapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $88.2 million for Q1 2026.

• Quarterly Short-term Investments rose 63.38% year-over-year to $88.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.2 million (up 63.38% YoY) and the FY2025 annual result came in at $107.7 million, up 73.26% from the prior year.
• Short-term Investments was $88.2 million for Q1 2026 at Black Diamond Therapeutics, down from $107.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $125.7 million in Q1 2022 and bottomed at $47.6 million in Q2 2023.
• A 5-year average of $87.1 million and a median of $89.3 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2023 — Short-term Investments slumped 54.64% — and 2024, when it soared 89.26%.
• Black Diamond Therapeutics' Short-term Investments stood at $88.5 million in 2022, then decreased by 15.04% to $75.2 million in 2023, then fell by 17.35% to $62.1 million in 2024, then surged by 73.26% to $107.7 million in 2025, then declined by 18.09% to $88.2 million in 2026.
• Business Quant data shows BDTX's Short-term Investments at $88.2 million in Q1 2026, $107.7 million in Q4 2025, and $104.6 million in Q3 2025.